Detoxified pneumolysin derivative plym2 directly protects against pneumococcal infection via induction of inflammatory cytokines

References

• Alexander JE, Lock RA, Peeters CC, et al. (1994). Immunization of mice with Pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun, 62, 5683–8
   PubMed Web of Science ®Google Scholar
• Berry AM, Alexander JE, Mitchell TJ, et al. (1995). Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect Immun, 63, 1969–74
   PubMed Web of Science ®Google Scholar
• Boulnois GJ, Paton JC, Mitchell TJ, Andrew PW. (1991). Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol Microbiol, 5, 2611–6
   PubMed Web of Science ®Google Scholar
• Braun JS, Novak R, Gao G, et al. (1999). Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect Immun, 67, 3750–6
   PubMedGoogle Scholar
• Dinarello CA. (2000). Proinflammatory cytokines. Chest, 118, 503–8
   PubMed Web of Science ®Google Scholar
• Ferrante A, Rowan-Kelly B, Paton JC. (1984). Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun, 46, 585–9
   PubMedGoogle Scholar
• Ferreira DM, Areas AP, Darrieux M, et al. (2006). DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae. FEMS Immunol Med Microbiol, 46, 291–7
   PubMedGoogle Scholar
• Forsythe P, Bienenstock J. (2010). Immunomodulation by commensal and probiotic bacteria. Immunol Invest, 39, 429–48
   PubMed Web of Science ®Google Scholar
• Gilbert RJ, Jimenez JL, Chen S, et al. (1999). Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell, 97, 647–55
   PubMed Web of Science ®Google Scholar
• Harvey RM, Ogunniyi AD, Chen AY, Paton JC. (2011). Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae in the blood. Infect Immun, 79, 4122–30
   PubMedGoogle Scholar
• Hersh D, Weiss J, Zychlinsky A. (1998). How bacteria initiate inflammation: aspects of the emerging story. Microbiology, 1(1), 43–8
   Google Scholar
• Houldsworth S, Andrew PW, Mitchell TJ. (1994). Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun, 62, 1501–3
   PubMed Web of Science ®Google Scholar
• Johnson MK, Boese-Marrazzo D, Pierce WA Jr. (1981). Effects of pneumolysin on human polymorphonuclear leukocytes and platelets. Infect Immun, 34, 171–6
   PubMed Web of Science ®Google Scholar
• Kirkham LA, Kerr AR, Douce GR, et al. (2006). Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun, 74, 586–93
   PubMed Web of Science ®Google Scholar
• Liu L, Johnson HL, Cousens S, et al. (2012). Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet, 379, 2151–61
   PubMed Web of Science ®Google Scholar
• Malley R, Henneke P, Morse SC, et al. (2003). Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci, 100, 1966–71
   PubMed Web of Science ®Google Scholar
• Mitchell TJ, Andrew PW, Saunders FK, et al. (1991). Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol Microbiol, 5, 1883–8
   PubMed Web of Science ®Google Scholar
• Nandoskar M, Ferrante A, Bates EJ, et al. (1986). Inhibition of human monocyte respiratory burst, degranulation, phospholipid methylation and bactericidal activity by pneumolysin. Immunology, 59, 515–20
   PubMedGoogle Scholar
• O'Brien KL, Wolfson LJ, Watt JP, et al. (2009). Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet, 374, 893–902
   PubMed Web of Science ®Google Scholar
• Ogunniyi AD, Folland RL, Briles DE, et al. (2000). Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun, 68, 3028–33
   PubMed Web of Science ®Google Scholar
• Oloo EO, Yethon JA, Ochs MM, et al. (2011). Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against Pneumococcal disease. J Biol Chem, 286, 12133–40
   PubMed Web of Science ®Google Scholar
• Paton JC, Rowan-Kelly B, Ferrante A. (1984). Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun, 43, 1085–7
   PubMedGoogle Scholar
• Qadri Q, Rasool R, Afroze D, et al. (2014). Study of TLR4 and IL-8 gene polymorphisms in H. pylori-induced inflammation in gastric cancer in an ethnic Kashmiri population. Immunol Invest, 43, 324–36
   PubMed Web of Science ®Google Scholar
• Rubins JB, Charboneau D, Paton JC, et al. (1995). Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest, 95, 142–50
   PubMed Web of Science ®Google Scholar
• Rubins JB, Duane PG, Charboneau D, Janoff EN. (1992). Toxicity of pneumolysin to pulmonary endothelial cells in vitro. Infect Immun, 60, 1740–6
   PubMedGoogle Scholar
• Rubins JB, Duane PG, Clawson D, et al. (1993). Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun, 61, 1352–8
   PubMed Web of Science ®Google Scholar
• Shoma S, Tsuchiya K, Kawamura I, et al. (2008). Critical involvement of pneumolysin in production of Interleukin-1 and Caspase-1-dependent cytokines in infection with Streptococcus pneumoniae in vitro: a novel function of Pneumolysin in Caspase-1 activation. Infect Immun, 76, 1547–57
   PubMedGoogle Scholar
• Srivastava A, Henneke P, Visintin A, et al. (2005). The apoptotic response to pneumolysin is toll-like receptor 4 dependent and protects against Pneumococcal disease. Infect Immun, 73, 6479–87
   PubMedGoogle Scholar
• Yoo I-H, Shin H-S, Kim Y-J, et al. (2010). Role of pneumococcal pneumolysin in the induction of an inflammatory response in human epithelial cells. FEMS Immunol Med Microbiol, 60, 28–35
   PubMedGoogle Scholar
• Zhong W, Xu W, Wang H, et al. (2012). Mucosal immunization with caseinolytic protease X elicited cross-protective immunity against pneumococcal infection in mice. Exper Biol Med, 237, 694–702
   PubMed Web of Science ®Google Scholar